JO3068B1 - إيميدازوبيريميدينات كمثبطات كيناز akt - Google Patents

إيميدازوبيريميدينات كمثبطات كيناز akt

Info

Publication number
JO3068B1
JO3068B1 JOP/2012/0084A JOP20120084A JO3068B1 JO 3068 B1 JO3068 B1 JO 3068B1 JO P20120084 A JOP20120084 A JO P20120084A JO 3068 B1 JO3068 B1 JO 3068B1
Authority
JO
Jordan
Prior art keywords
imidazopyridazines
kinase inhibitors
akt kinase
akt
inhibitors
Prior art date
Application number
JOP/2012/0084A
Other languages
English (en)
Inventor
Hägebarth Andrea
Politz Oliver
Ulf Bomer
Neuhaus Roland
Ince Stuart
Barfacker Lars
Rehwinkel Hartmut
Briem Hans
Scott William
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Application granted granted Critical
Publication of JO3068B1 publication Critical patent/JO3068B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات Imidazopyridazines من الصيغة (I) عملية لإنتاجها واستخدامها.
JOP/2012/0084A 2011-04-07 2012-04-05 إيميدازوبيريميدينات كمثبطات كيناز akt JO3068B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07

Publications (1)

Publication Number Publication Date
JO3068B1 true JO3068B1 (ar) 2017-03-15

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0084A JO3068B1 (ar) 2011-04-07 2012-04-05 إيميدازوبيريميدينات كمثبطات كيناز akt

Country Status (42)

Country Link
US (2) US9206185B2 (ar)
EP (1) EP2694510B1 (ar)
JP (1) JP5906303B2 (ar)
KR (1) KR20140022057A (ar)
CN (1) CN103596957B (ar)
AP (1) AP3597A (ar)
AR (1) AR087148A1 (ar)
AU (1) AU2012238589B2 (ar)
BR (1) BR112013025777A2 (ar)
CA (1) CA2832374A1 (ar)
CL (1) CL2013002878A1 (ar)
CO (1) CO6862145A2 (ar)
CR (1) CR20130515A (ar)
CU (1) CU24263B1 (ar)
CY (1) CY1117163T1 (ar)
DK (1) DK2694510T3 (ar)
DO (1) DOP2013000226A (ar)
EA (1) EA024890B1 (ar)
EC (1) ECSP13013008A (ar)
ES (1) ES2558780T3 (ar)
GT (1) GT201300238A (ar)
HR (1) HRP20160011T1 (ar)
HU (1) HUE026323T2 (ar)
IL (1) IL228567A0 (ar)
JO (1) JO3068B1 (ar)
MA (1) MA35016B1 (ar)
ME (1) ME02316B (ar)
MX (1) MX336865B (ar)
NI (1) NI201300105A (ar)
PE (1) PE20141380A1 (ar)
PL (1) PL2694510T3 (ar)
PT (1) PT2694510E (ar)
RS (1) RS54480B1 (ar)
SG (1) SG193631A1 (ar)
SI (1) SI2694510T1 (ar)
SM (1) SMT201600001B (ar)
TN (1) TN2013000400A1 (ar)
TW (1) TWI535719B (ar)
UA (1) UA111739C2 (ar)
UY (1) UY34006A (ar)
WO (1) WO2012136776A1 (ar)
ZA (1) ZA201307223B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
TR201903981T4 (tr) 2008-06-16 2019-04-22 Univ Ohio State Res Found Kanser tedavisi için bileşikler.
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы
JP6106694B2 (ja) * 2012-01-10 2017-04-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換ピラゾロピリミジン類
US9260435B2 (en) * 2012-01-10 2016-02-16 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines as Akt kinase inhibitors
ES2686730T3 (es) * 2012-11-30 2018-10-19 Novartis Ag Composición farmacéutica novedosa
CN109568312A (zh) 2013-03-05 2019-04-05 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014158467A1 (en) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combination
EP2968343A4 (en) * 2013-03-14 2016-11-02 Epizyme Inc POLY THERAPY FOR TREATING CANCER
CN105899512A (zh) * 2014-01-09 2016-08-24 拜耳医药股份公司 可用于治疗过度增殖性和/或血管生成疾病的酰胺基团取代的咪唑并哒嗪
KR102611539B1 (ko) * 2016-11-28 2023-12-06 브리스톨-마이어스 스큅 컴퍼니 Gsk-3 억제제
EP3453706A1 (en) 2017-09-08 2019-03-13 Basf Se Pesticidal imidazole compounds

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1246621A4 (en) 1999-12-23 2004-11-24 Nitromed Inc NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
EP1268478B1 (en) 2000-03-31 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Phenyl-substituted imidazopyridines
CN1173975C (zh) 2000-04-27 2004-11-03 山之内制药株式会社 咪唑并吡啶衍生物
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
ATE380816T1 (de) 2003-07-30 2007-12-15 S A L V A T Lab Sa Substituierte imidazopyrimidine zur prävention und behandlung von krebs
EP1737843B1 (en) 2004-04-09 2011-02-23 Merck Sharp & Dohme Corp. Inhibitors of akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
CN101006062A (zh) 2004-08-24 2007-07-25 巴斯福股份公司 用作生产离子液体的起始化合物的咪唑甲基亚硫酸盐
CA2589084A1 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Inhibitors of akt activity
CA2609299A1 (en) 2005-05-20 2006-11-23 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
ES2409168T3 (es) 2005-06-10 2013-06-25 Merck Sharp & Dohme Corp. Inhibidores de la actividad Akt
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
EP2176259B1 (en) 2007-08-14 2011-03-30 Bayer Schering Pharma Aktiengesellschaft Fused imidazoles for cancer treatment
PE20090944A1 (es) 2007-08-14 2009-08-09 Bayer Schering Pharma Ag PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
WO2009086130A1 (en) 2007-12-21 2009-07-09 Wyeth Imidazo [1,2-b] pyridazine compounds as modulators of liver x receptors
WO2009148916A1 (en) 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AU2010208480A1 (en) 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
PE20120534A1 (es) 2009-02-13 2012-05-10 Bayer Pharma AG PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
WO2012007345A2 (en) * 2010-07-12 2012-01-19 Bayer Pharma Aktiengesellschaft Substituted imidazo[1,2-a]pyrimidines and -pyridines
US8987273B2 (en) * 2010-07-28 2015-03-24 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-B]pyridazines
EA024890B1 (ru) * 2011-04-07 2016-10-31 Байер Интеллектчуал Проперти Гмбх Имидазопиридазины в качестве ингибиторов akt киназы

Also Published As

Publication number Publication date
KR20140022057A (ko) 2014-02-21
EA024890B1 (ru) 2016-10-31
EA201301130A1 (ru) 2014-07-30
WO2012136776A1 (en) 2012-10-11
ECSP13013008A (es) 2013-12-31
PL2694510T3 (pl) 2016-03-31
HRP20160011T1 (hr) 2016-02-12
ZA201307223B (en) 2014-12-23
SMT201600001B (it) 2016-02-25
ES2558780T3 (es) 2016-02-08
EP2694510A1 (en) 2014-02-12
CR20130515A (es) 2013-12-04
AU2012238589A1 (en) 2013-11-07
CO6862145A2 (es) 2014-02-10
CN103596957B (zh) 2016-12-07
PT2694510E (pt) 2016-02-08
SI2694510T1 (sl) 2016-02-29
US9604989B2 (en) 2017-03-28
AP2013007215A0 (en) 2013-10-31
TW201245204A (en) 2012-11-16
CU20130135A7 (es) 2014-02-28
DOP2013000226A (es) 2013-11-15
TN2013000400A1 (en) 2015-03-30
MX2013011699A (es) 2014-01-31
JP5906303B2 (ja) 2016-04-20
AP3597A (en) 2016-02-19
HUE026323T2 (en) 2016-05-30
DK2694510T3 (en) 2016-01-18
UY34006A (es) 2012-10-31
AR087148A1 (es) 2014-02-26
SG193631A1 (en) 2013-11-29
ME02316B (me) 2016-06-20
GT201300238A (es) 2015-04-06
IL228567A0 (en) 2013-12-31
RS54480B1 (en) 2016-06-30
CL2013002878A1 (es) 2014-05-02
UA111739C2 (uk) 2016-06-10
CU24263B1 (es) 2017-07-04
EP2694510B1 (en) 2015-10-14
CN103596957A (zh) 2014-02-19
US9206185B2 (en) 2015-12-08
PE20141380A1 (es) 2014-10-18
MA35016B1 (fr) 2014-04-03
TWI535719B (zh) 2016-06-01
US20140113901A1 (en) 2014-04-24
NZ616270A (en) 2015-09-25
BR112013025777A2 (pt) 2016-12-20
MX336865B (es) 2016-02-04
AU2012238589B2 (en) 2017-02-16
US20150368250A1 (en) 2015-12-24
JP2014510127A (ja) 2014-04-24
NI201300105A (es) 2014-07-14
CA2832374A1 (en) 2012-10-11
CY1117163T1 (el) 2017-04-05

Similar Documents

Publication Publication Date Title
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX355728B (es) Inhibidores de cinasas.
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
MX339873B (es) Inhibidores de serina/treonina cinasa.
GEP201706745B (en) Forms of rifaximin and usage thereof
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
PH12015500363A1 (en) Prodrugs of amino quinazoline kinase inhibitor
NZ711192A (en) Process for making benzoxazepin compounds
GEP201706626B (en) Synthesis of (s)-nifuratel
HK1210616A1 (en) Process for the preparation of c-fms kinase inhibitors c-fms
GB201107985D0 (en) Process
NZ720805A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
AU2013314244A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
ZA201301799B (en) Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation
MX2014009084A (es) Derivados de pirimidooxazocina como inhibidores de mtor.
MX2012014796A (es) Proceso para preparar 4-hidroxipiridinas.
IN2014DN07191A (ar)
TN2013000128A1 (en) Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation
MY162973A (en) New process for the synthesis of agomelatine
UA77456U (ru) Способ профилактики гингивита